Showing results (71-80 of 80) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Cancer Management and Research|December 9, 2020
Long-Term Results of Concurrent Chemoradiotherapy Combined with Anti-EGFR Monoclonal Antibody Prior to Surgery in Locally Advanced Cervical Cancer: A Single-Institute Prospective StudyDefeng Qing, Yuying Wu, Xu Liu, et al.Cell Death & Disease|March 30, 2022
Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunctionHui Wang, Daoyuan Lv, Song Jiang, et al.Scientific Reports|May 7, 2024
Identification of early coagulation changes associated with survival outcomes post severe burns from multiple perspectivesShengyu Huang, Qimin Ma, Xincheng Liao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I StudyMinjiang Chen, Iurie Bulat, Marina Maglakelidze, et al.Burns & Trauma|July 2, 2021
Consensus on the application of negative pressure wound therapy of diabetic foot woundsShizhao Ji, Xiaobin Liu, Jie Huang, et al.JAMA Network Open|June 11, 2024
Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical TrialYating Wei, Yi Li, Xiaojian Li, et al.Cancer Communications (London, England)|April 2, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.Lung Cancer (Amsterdam, Netherlands)|May 10, 2023
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studiesSheng Yang, Shiman Wu, Yanqiu Zhao, et al.The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.Pageof 8